<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 獲取免費報告) 首席財務官 Mark Ragosa 於 11 月 12 日星期三出售了 19,900 股該股票。股票以平均價格 $40.94 出售，總價值為 $814,706.00。交易後，首席財務官持有該公司 31,086 股股票，價值約為 $1,272,660.84。這筆交易代表其持股減少了 39.03%。該交易已在向 SEC 提交的文件中披露，具體內容可通過此鏈接查看。</p>
<p>Mark Ragosa 最近還進行了以下交易：</p>
<ul>
<li>在 10 月 28 日星期二，Mark Ragosa 出售了 100 股 Kiniksa Pharmaceuticals International 股票。這些股票以平均價格 $41.00 出售，總價值為 $4,100.00。</li>
</ul>
<h2>Kiniksa Pharmaceuticals International 股票上漲 0.1%</h2>
<p>在週五的午盤交易中，NASDAQ:KNSA 股票上漲 $0.03，達到 $40.32。該股票交易量為 264,948 股，而其平均交易量為 622,492 股。該公司的市值為 30.6 億美元，市盈率為 89.60，貝塔值為 0.16。Kiniksa Pharmaceuticals International, plc 的一年低點為 $17.82，一年高點為 $42.05。該股票的 50 日簡單移動平均線為 $37.85，200 日簡單移動平均線為 $32.23。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近於 10 月 28 日星期二發佈了其財報。公司報告本季度每股收益為 $0.23，低於市場共識預期的 $0.31，差額為 ($0.08)。Kiniksa Pharmaceuticals International 的淨利潤率為 6.01%，股本回報率為 7.46%。該公司本季度的收入為 $1.8086 億，低於市場共識預期的 $1.6664 億。去年同期，該公司每股收益為 ($0.18)。公司的收入同比增長 61.2%。Kiniksa Pharmaceuticals International 已設定其 2025 財年的每股收益指導。分析師預計 Kiniksa Pharmaceuticals International, plc 本財年的每股收益將為 -0.55。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者最近對 KNSA 的持倉進行了調整。Cerity Partners LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持股增加了 42.3%。Cerity Partners LLC 現在擁有 40,708 股該公司的股票，價值 $904,000，此前在上個季度購買了額外的 12,110 股。CWM LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 867.4%。CWM LLC 現在擁有 22,114 股該公司的股票，價值 $491,000，此前在此期間購買了額外的 19,828 股。Victory Capital Management Inc. 在第一季度獲得了 Kiniksa Pharmaceuticals International 的新股份，價值約為 $1,184,000。Knights of Columbus Asset Advisors LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 2.7%。Knights of Columbus Asset Advisors LLC 現在擁有 62,624 股該公司的股票，價值 $1,391,000，此前在上個季度購買了額外的 1,658 股。最後，Sound View Wealth Advisors Group LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持股增加了 4.0%。Sound View Wealth Advisors Group LLC 現在擁有 14,657 股該公司的股票，價值 $326,000，此前在此期間購買了額外的 568 股。53.95% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾位研究分析師最近對 KNSA 股票發表了評論。花旗集團將 Kiniksa Pharmaceuticals International 的目標價格從 $45.00 上調至 $50.00，並在 10 月 17 日星期五的報告中給予該股票 &#34;買入&#34; 評級。Wedbush 在 10 月 28 日星期二的研究報告中重申了 &#34;跑贏大盤&#34; 評級，並將 Kiniksa Pharmaceuticals International 的目標價格設定為 $48.00（上調自 $44.00）。富國銀行將 Kiniksa Pharmaceuticals International 的目標價格從 $42.00 上調至 $45.00，並在 9 月 25 日星期四的研究報告中給予該公司 &#34;增持&#34; 評級。華爾街禪在 11 月 2 日星期日的報告中將 Kiniksa Pharmaceuticals International 的評級從 &#34;強力買入&#34; 下調至 &#34;買入&#34;。最後，傑富瑞金融集團在 7 月 29 日星期二的研究報告中將 Kiniksa Pharmaceuticals International 的目標價格從 $45.00 上調至 $54.00，並給予該公司 &#34;買入&#34; 評級。六位研究分析師對該股票給予了買入評級，兩位分析師對該公司的股票給予了持有評級。根據 MarketBeat 的數據，Kiniksa Pharmaceuticals International 當前的平均評級為 &#34;適度買入&#34;，平均目標價格為 $52.00。</p>
<p><strong>獲取我們關於 KNSA 的最新研究報告</strong></p>
<h2>關於 Kiniksa Pharmaceuticals International</h2>
<p>(獲取免費報告)</p>
<p>Kiniksa Pharmaceuticals, Ltd. 是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球面臨重大未滿足醫療需求的患者。其產品候選藥物包括 ARCALYST，一種針對複發性心包炎的白細胞介素-1α 和白細胞介素-1β；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的 II 期臨牀試驗；Vixarelimab，一種單克隆抗體，正在進行針對結節性瘙癢症的 2b 期臨牀試驗；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應的關鍵 T 細胞共刺激信號。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>3 只股票可以保護您的投資組合免受冠狀病毒傳播的影響</li>
<li>如果您等待下跌，Micron Technology 可能會讓您錯失良機</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>3 只悄然推動 AI 和科技革命的股票</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>Jefferies 告訴 NVIDIA 讓位，選擇 Broadcom 作為頂級半導體股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Kiniksa Pharmaceuticals International 嗎？</h2>
<p>在您考慮 Kiniksa Pharmaceuticals International 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
<p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KNSA

<p>Kiniksa Pharmaceuticals International 的首席財務官 Mark Ragosa 出售了 19,900 股，減少了 39.03% 的持股比例。這些股票以每股 40.94 美元的價格出售，總計 814,706 美元。出售後，Ragosa 擁有 31,086 股，價值 1,272,660.84 美元。該交易已在 SEC 文件中披露。該公司的股票最近受到機構的關注，並且分析師進行了升級，多家機構提高了價格目標</p>

<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 19,900 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $40.94, for a total value of $814,706.00. Following the transaction, the chief financial officer owned 31,086 shares of the company's stock, valued at approximately $1,272,660.84. This trade represents a 39.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 獲取免費報告) 首席財務官 Mark Ragosa 於 11 月 12 日星期三出售了 19,900 股該股票。股票以平均價格 $40.94 出售，總價值為 $814,706.00。交易後，首席財務官持有該公司 31,086 股股票，價值約為 $1,272,660.84。這筆交易代表其持股減少了 39.03%。該交易已在向 SEC 提交的文件中披露，具體內容可通過此鏈接查看。</p>
</div><p>Mark Ragosa also recently made the following trade(s):</p>
<div class="lb-trans"><p>Mark Ragosa 最近還進行了以下交易：</p>
</div><ul>
<li>On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 10 月 28 日星期二，Mark Ragosa 出售了 100 股 Kiniksa Pharmaceuticals International 股票。這些股票以平均價格 $41.00 出售，總價值為 $4,100.00。</li>
</ul>
</div><h2>Kiniksa Pharmaceuticals International Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票上漲 0.1%</h2>
</div><p>Shares of NASDAQ:KNSA traded up $0.03 during mid-day trading on Friday, reaching $40.32. 264,948 shares of the stock were exchanged, compared to its average volume of 622,492. The company has a market cap of $3.06 billion, a P/E ratio of 89.60 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $42.05. The stock's 50 day simple moving average is $37.85 and its 200-day simple moving average is $32.23.</p>
<div class="lb-trans"><p>在週五的午盤交易中，NASDAQ:KNSA 股票上漲 $0.03，達到 $40.32。該股票交易量為 264,948 股，而其平均交易量為 622,492 股。該公司的市值為 30.6 億美元，市盈率為 89.60，貝塔值為 0.16。Kiniksa Pharmaceuticals International, plc 的一年低點為 $17.82，一年高點為 $42.05。該股票的 50 日簡單移動平均線為 $37.85，200 日簡單移動平均線為 $32.23。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. The company's revenue was up 61.2% on a year-over-year basis. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近於 10 月 28 日星期二發佈了其財報。公司報告本季度每股收益為 $0.23，低於市場共識預期的 $0.31，差額為 ($0.08)。Kiniksa Pharmaceuticals International 的淨利潤率為 6.01%，股本回報率為 7.46%。該公司本季度的收入為 $1.8086 億，低於市場共識預期的 $1.6664 億。去年同期，該公司每股收益為 ($0.18)。公司的收入同比增長 61.2%。Kiniksa Pharmaceuticals International 已設定其 2025 財年的每股收益指導。分析師預計 Kiniksa Pharmaceuticals International, plc 本財年的每股收益將為 -0.55。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors have recently made changes to their positions in KNSA. Cerity Partners LLC lifted its holdings in Kiniksa Pharmaceuticals International by 42.3% during the 1st quarter. Cerity Partners LLC now owns 40,708 shares of the company's stock valued at $904,000 after purchasing an additional 12,110 shares during the last quarter. CWM LLC raised its position in shares of Kiniksa Pharmaceuticals International by 867.4% in the first quarter. CWM LLC now owns 22,114 shares of the company's stock valued at $491,000 after purchasing an additional 19,828 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $1,184,000. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 62,624 shares of the company's stock worth $1,391,000 after buying an additional 1,658 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 4.0% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after buying an additional 568 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近對 KNSA 的持倉進行了調整。Cerity Partners LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持股增加了 42.3%。Cerity Partners LLC 現在擁有 40,708 股該公司的股票，價值 $904,000，此前在上個季度購買了額外的 12,110 股。CWM LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 867.4%。CWM LLC 現在擁有 22,114 股該公司的股票，價值 $491,000，此前在此期間購買了額外的 19,828 股。Victory Capital Management Inc. 在第一季度獲得了 Kiniksa Pharmaceuticals International 的新股份，價值約為 $1,184,000。Knights of Columbus Asset Advisors LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 2.7%。Knights of Columbus Asset Advisors LLC 現在擁有 62,624 股該公司的股票，價值 $1,391,000，此前在上個季度購買了額外的 1,658 股。最後，Sound View Wealth Advisors Group LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持股增加了 4.0%。Sound View Wealth Advisors Group LLC 現在擁有 14,657 股該公司的股票，價值 $326,000，此前在此期間購買了額外的 568 股。53.95% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several research analysts recently commented on KNSA shares. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, October 17th. Wedbush restated an &#34;outperform&#34; rating and set a $48.00 price objective (up from $44.00) on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, October 28th. Wells Fargo &amp; Company lifted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 25th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, November 2nd. Finally, Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $52.00.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 KNSA 股票發表了評論。花旗集團將 Kiniksa Pharmaceuticals International 的目標價格從 $45.00 上調至 $50.00，並在 10 月 17 日星期五的報告中給予該股票 &#34;買入&#34; 評級。Wedbush 在 10 月 28 日星期二的研究報告中重申了 &#34;跑贏大盤&#34; 評級，並將 Kiniksa Pharmaceuticals International 的目標價格設定為 $48.00（上調自 $44.00）。富國銀行將 Kiniksa Pharmaceuticals International 的目標價格從 $42.00 上調至 $45.00，並在 9 月 25 日星期四的研究報告中給予該公司 &#34;增持&#34; 評級。華爾街禪在 11 月 2 日星期日的報告中將 Kiniksa Pharmaceuticals International 的評級從 &#34;強力買入&#34; 下調至 &#34;買入&#34;。最後，傑富瑞金融集團在 7 月 29 日星期二的研究報告中將 Kiniksa Pharmaceuticals International 的目標價格從 $45.00 上調至 $54.00，並給予該公司 &#34;買入&#34; 評級。六位研究分析師對該股票給予了買入評級，兩位分析師對該公司的股票給予了持有評級。根據 MarketBeat 的數據，Kiniksa Pharmaceuticals International 當前的平均評級為 &#34;適度買入&#34;，平均目標價格為 $52.00。</p>
</div><p><strong>Get Our Latest Research Report on KNSA</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 KNSA 的最新研究報告</strong></p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>關於 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd. 是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球面臨重大未滿足醫療需求的患者。其產品候選藥物包括 ARCALYST，一種針對複發性心包炎的白細胞介素-1α 和白細胞介素-1β；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的 II 期臨牀試驗；Vixarelimab，一種單克隆抗體，正在進行針對結節性瘙癢症的 2b 期臨牀試驗；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應的關鍵 T 細胞共刺激信號。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Jefferies Tells NVIDIA to Step Aside, Picks Broadcom as Top Semiconductor Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>3 只股票可以保護您的投資組合免受冠狀病毒傳播的影響</li>
<li>如果您等待下跌，Micron Technology 可能會讓您錯失良機</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>3 只悄然推動 AI 和科技革命的股票</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>Jefferies 告訴 NVIDIA 讓位，選擇 Broadcom 作為頂級半導體股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Kiniksa Pharmaceuticals International 嗎？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Kiniksa Pharmaceuticals International 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Mark Ragosa 出售了 19,900 股 Kiniksa Pharmaceuticals International（納斯達克代碼：KNSA）的股票